QPPV.COM KNOWLEDGE ASSESSMENT

Depemokimab: Classification, History, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Depemokimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why may an interruption of depemokimab not constitute a complete dechallenge?

Its extended dosing interval and persistent biological effect may mean that pharmacological activity continues after treatment is held Dechallenge is valid only if the patient receives a higher dose after interruption An interruption is never relevant to causality for biological medicines A dechallenge can be complete only when a rechallenge is positive

Question 2 of 10 Why is exact batch information valuable in a case involving a suspected product-quality issue?

It enables linkage with storage, distribution, preparation and other cases that may share a product or batch It establishes that the product caused the event without further investigation It replaces the need to document the clinical phenotype It is relevant only for financial reconciliation and not for pharmacovigilance

Question 3 of 10 A follow-up process closes a case after the patient's next scheduled dose, although symptoms recur months later. Which system weakness does this illustrate?

Failure to account for delayed or recurrent events associated with an extended dosing interval and potentially persistent biological effect Appropriate case closure because events after the next dose cannot be treatment-related A coding problem that can be solved without reviewing the chronology A product-quality issue proven solely by the recurrence

Question 4 of 10 Before concluding that a cluster represents a new depemokimab safety signal, which comparison is most important?

Compare the cases with background disease rates, class effects, concomitant medicines, reporting stimulation, practice changes and product information Compare only the number of cases with the number of doses distributed Assume a signal exists whenever a cluster contains three or more preferred terms Use only the reporter's stated causality assessment

Question 5 of 10 Why should the target IL-5 be retained in a pharmacovigilance assessment rather than recording only the clinical event term?

It identifies the biological pathway whose modulation can support both benefit hypotheses and plausible safety concerns It proves that every event occurring after treatment is caused by depemokimab It replaces the need to document disease severity and concomitant medicines It determines the seriousness classification independently of the clinical outcome

Question 6 of 10 What is the principal practical value of capturing baseline and serial laboratory or functional findings?

They help distinguish a new treatment-emergent change from a pre-existing abnormality, disease progression or transient fluctuation They automatically establish a causal relationship if the post-treatment value is abnormal They are needed only for periodic reports and have no value in individual cases They replace the need to document symptoms, treatment and clinical outcome

Question 7 of 10 In periodic benefit-risk evaluation, why must the benefit population be preserved rather than pooling all treated patients?

Benefit and background risk may differ by authorised indication, age, disease severity, treatment phase and combination regimen Pooling is always prohibited for biological medicines under all circumstances Benefit is independent of treatment intent and disease characteristics Only safety outcomes matter in periodic benefit-risk evaluation

Question 8 of 10 A case describes worsening asthma after corticosteroid tapering while depemokimab exposure is ongoing. What is the most appropriate interpretation?

Corticosteroid tapering and disease control should be considered as competing explanations alongside possible treatment failure or treatment-related effects The worsening must be classified as an adverse reaction because it occurred during exposure The event should be ignored because lack of effect is not relevant to pharmacovigilance The event should be attributed to depemokimab only if the patient was previously untreated

Question 9 of 10 Which governance evidence best demonstrates that the pharmacovigilance system is functioning effectively for depemokimab?

Evidence that relevant cases were followed up, medically assessed, traceably coded and incorporated into appropriate aggregate review A written procedure that has never been tested against actual cases A high volume of database entries without documented medical review A product dictionary without reconciliation to quality complaints or distribution records

Question 10 of 10 Which stratification is most likely to improve interpretation of a possible safety signal for depemokimab?

Indication, disease severity, treatment line, combination status, duration, age, baseline organ function and prior therapy Reporter profession alone Calendar quarter without clinical or exposure information Country of report only, regardless of differences in indication or treatment practice

QPPV.com

Depemokimab: Classification, History, Mechanism, Safety and Pharmacovigilance

Cookie Settings